ArticleCancer cell international2026
DNA damage response signature-based prognostic genes for intrahepatic cholangiocarcinoma: a combined analysis of machine learning and biological experiments.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIntrahepatic cholangiocarcinoma (ICC) is a highly aggressive subtype of primary liver cancer with insidious onset, early metastasis, and poor prognosis. DNA damage response (DDR) dysfunction is linked to ICC tumorigenesis, progression, and drug resistance. However, the detailed mechanisms remain underexplored.
methodsDDR activity was quantified by ssGSEA across 6 independent ICC cohorts. DDR risk model was analyzed using 10 machine learning algorithms to construct 101 combined models, and the optimal Lasso + RSF model was adopted by c-index. The core gene SFN was selected for experimental validation. Single‑cell RNA sequencing and spatial transcriptomics were used to explore cellular localization and tissue distribution of signature genes. In vitro assays were performed in ICC cell lines after SFN knockdown to assess cell proliferation and chemosensitivity.
resultsThe DDR risk model showed stable prognostic performance in training and external validation cohorts. High‑risk patients exhibited poor prognosis, immunosuppressive microenvironment and reduced sensitivity to multiple chemotherapeutic agents. SFN was specifically enriched in malignant cells. Knockdown of SFN significantly suppressed cell proliferation and colony formation, enhanced sensitivity to cisplatin and gemcitabine, and increased γ‑H2AX expression indicating elevated DNA double‑strand breaks.
conclusionsWe constructed a robust DDR‑based prognostic model for ICC that enables accurate risk stratification and prediction of therapeutic response. SFN serves as a critical driver of chemoresistance and a potential therapeutic target. These results offer novel biomarkers and mechanistic insights to facilitate precision medicine for ICC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.